Solomon Moshkevich, President, Clinical Diagnostics at Natera, shared a post on LinkedIn:
“I sat for an interview with AJMC – The American Journal of Managed Care, to discuss the extraordinary health economic potential of precision MRD-guided care in oncology.
Mary Caffrey from AJMC captured it beautifully: using Signatera MRD testing, at least half of the patients with early-stage bladder cancer, colorectal cancer, and breast cancer could safely avoid toxic therapies that cost the healthcare system BILLIONS of dollars annually.”
Other articles featuring Solomon Moshkevich on OncoDaily.